ROCKVILLE, Md. , Oct. 18, 2024 /PRNewswire/ -- REGENXBIO Inc.
(Nasdaq: RGNX ) today announced that it will present new interim data evaluating subretinal delivery of ABBV-RGX-314 in patients with bilateral wet age-related macular degeneration (wet AMD) at the American Academy of Ophthalmology 2024 annual meeting. ABBV-RGX-314 is an investigational one-time AAV Therapeutic being developed in collaboration with AbbVie for the treatment of wet AMD, diabetic retinopathy and other additional chronic retinal conditions. New data will be presented as follows: Title: Subretinal Delivery of Investigational ABBV-RGX-314 as a Gene Therapy for nAMD: First Time Results of a Fellow Eye Bilateral Dosing Study (abstract 30080148) Presenter: Arshad Khanani M.
D ., M.A.
, FASRS, Director of Clinical Research at Sierra Eye Associates Date/Time: Saturday, October 19, 2024 , at 11:59 a.m. ET Encore presentations will be presented as follows: Title: A Phase 2 Dose-Escalation Study Evaluating Suprachoroidal Delivery of Investigational ABBV-RGX-314 Gene Therapy for DR (abstract 30078795) Presenter: Arshad Khanani M.
D ., M.A.
, FASRS, Director of Clinical Research at Sierra Eye Associates Date/Time: Monday, October 21, 2024 , at 10:45 a.m. ET Title: Long-Term Follow-Up Study Results from the Investigational Phase I/IIa ABBV-RGX-314 Subretinal Delivery Gene Therapy Program in nAMD (abstract 30079480) Presenter: Philip P.
Storey , M.D., Austin Retina Associates Date/Time: Monday, October 21, 2024 , at 12:.